本页面由Tiger Trade Technology Pte. Ltd.提供服务

Vir Biotechnology, Inc.

9.21
-0.2750-2.90%
成交量:123.24万
成交额:1,127.56万
市值:14.45亿
市盈率:-2.91
高:9.49
开:9.43
低:8.99
收:9.48
52周最高:10.94
52周最低:4.16
股本:1.57亿
流通股本:1.07亿
量比:0.60
换手率:1.15%
股息:- -
股息率:- -
每股收益(TTM):-3.1619
每股收益(LYR):-3.1619
净资产收益率:-45.73%
总资产收益率:-24.36%
市净率:1.89
市盈率(LYR):-2.91

数据加载中...

2026/03/04

重要事件披露

Form 8-K - Current report
2026/03/03

关联方拟减持公告

Form 144 | VIR BIO高管 Vicki Lee Sato 拟减持88000股,总价约80万美元
2026/03/02

重要事件披露

Form 8-K - Current report
2026/02/26

重要事件披露

Form 8-K - Current report
2026/02/25

关联方拟减持公告

Form 144 | Vir Biotechnology 股东 SVF Endurance (Cayman) Limited 拟减持40万股,总价约380万美元
2026/02/25

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2026/02/25

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2026/02/24

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2026/02/24

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2026/02/24

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2026/02/24

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2026/02/24

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2026/02/24

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2026/02/23

员工持股计划

Form S-8 - Securities to be offered to employees in employee benefit plans
2026/02/23

年度报告

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
2026/02/23

重要事件披露

Form 8-K - Current report
2026/02/23

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2026/02/23

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2026/02/23

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2026/02/23

关联方拟减持公告

Form 144 - Report of proposed sale of securities